NRx is excited about the most recent report published by the Israeli Institute of Biological Research on the BriLife® vaccine. The scientific report shows serologic response against the Omicron variant in patients vaccinated during the phase 2 clinical trial of BriLife® against Sars-CoV-2 coronavirus. Ten of 13 vaccinated subjects demonstrated detectable neutralizing antibody against Omicron. […]
As reported last night in the Times of Israel, the former Director of the Israel Institute for Biological Research (IIBR) disclosed that the BriLife™ Vaccine has shown initial signs of effectiveness against the Omicron variant. This is the information that caused NRx to advise the public that we are moving towards a vanguard trial of […]
NRx Pharmaceuticals today was advised that the independent Data Safety Monitoring Board overseeing the phase 2 trial of the BriLife vaccine has concluded its safety analysis.